Compare PRG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | ARDX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2014 |
| Metric | PRG | ARDX |
|---|---|---|
| Price | $31.33 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $47.50 | $15.14 |
| AVG Volume (30 Days) | 328.6K | ★ 3.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.59 | N/A |
| Revenue | ★ $2,409,223,000.00 | $2,607,000.00 |
| Revenue This Year | $23.77 | $37.75 |
| Revenue Next Year | $7.91 | $34.24 |
| P/E Ratio | $8.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.47 | $3.50 |
| 52 Week High | $41.14 | $8.40 |
| Indicator | PRG | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 45.34 |
| Support Level | $29.80 | $5.49 |
| Resistance Level | $31.52 | $6.23 |
| Average True Range (ATR) | 1.02 | 0.24 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 62.04 | 25.31 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.